Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;2(3):153-161.
doi: 10.1007/s13539-011-0034-6. Epub 2011 Aug 2.

The Selective Androgen Receptor Modulator GTx-024 (Enobosarm) Improves Lean Body Mass and Physical Function in Healthy Elderly Men and Postmenopausal Women: Results of a Double-Blind, Placebo-Controlled Phase II Trial

Affiliations
Free PMC article

The Selective Androgen Receptor Modulator GTx-024 (Enobosarm) Improves Lean Body Mass and Physical Function in Healthy Elderly Men and Postmenopausal Women: Results of a Double-Blind, Placebo-Controlled Phase II Trial

James T Dalton et al. J Cachexia Sarcopenia Muscle. .
Free PMC article

Abstract

BACKGROUND: Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage renal disease, and other chronic conditions and results in significant morbidity and mortality. GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) that has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men. GTx-024 has demonstrated promising pharmacologic effects in preclinical studies and favorable safety and pharmacokinetic profiles in phase I investigation. METHODS: A 12-week double-blind, placebo-controlled phase II clinical trial was conducted to evaluate GTx-024 in 120 healthy elderly men (>60 years of age) and postmenopausal women. The primary endpoint was total lean body mass assessed by dual energy X-ray absorptiometry, and secondary endpoints included physical function, body weight, insulin resistance, and safety. RESULTS: GTx-024 treatment resulted in dose-dependent increases in total lean body mass that were statistically significant (P < 0.001, 3 mg vs. placebo) and clinically meaningful. There were also significant improvements in physical function (P = 0.013, 3 mg vs. placebo) and insulin resistance (P = 0.013, 3 mg vs. placebo). The incidence of adverse events was similar between treatment groups. CONCLUSION: GTx-024 showed a dose-dependent improvement in total lean body mass and physical function and was well tolerated. GTx-024 may be useful in the prevention and/or treatment of muscle wasting associated with cancer and other chronic diseases.

Figures

Fig. 1
Fig. 1
Percentage change from baseline to day 86/EOS in total lean body mass: evaluable population. EOS end of study, *P < 0.001 3 mg vs. placebo (T test)
Fig. 2
Fig. 2
Percentage change from baseline to day 86/EOS in stair climb power: evaluable population. EOS end of study, *P = 0.013 3 mg vs. placebo (T test)

Similar articles

See all similar articles

Cited by 94 articles

See all "Cited by" articles

References

    1. Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol. 2005;37(5):1084–1104. doi: 10.1016/j.biocel.2004.10.003. - DOI - PubMed
    1. Baracos VE. Management of muscle wasting in cancer-associated cachexia. Cancer. 2001;92(6 Suppl):1669–1677. doi: 10.1002/1097-0142(20010915)92:6+<1669::AID-CNCR1495>3.0.CO;2-S. - DOI - PubMed
    1. Roubenoff R. Sarcopenia and its implications for the elderly. Eur J Clin Nutr. 2000;54(Suppl 3):S40–S47. - PubMed
    1. Tan BHL, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11(4):400–407. doi: 10.1097/MCO.0b013e328300ecc1. - DOI - PubMed
    1. Guralnick JM. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556–561. doi: 10.1056/NEJM199503023320902. - DOI - PubMed

LinkOut - more resources

Feedback